Doctors are often overwhelmed by the sheer volume of medical information they must process daily. German-founded AMBOSS, created by physicians for physicians, has been tackling this challenge head-on—streamlining medical knowledge access when it matters most.
Now, the company is entering a new growth phase after raising an impressive €240 million in funding. The round attracted fresh long-term investors, including KIRKBI, M&G Investments, and Lightrock, with additional backing from existing shareholders. This capital injection strengthens AMBOSS’s global ambitions as it plans to expand its reach beyond doctors to empower a broader range of healthcare professionals.
With this funding boost, AMBOSS is set to accelerate international growth and broaden its offerings to support nurses, allied health providers, and other medical professionals. By expanding access to its platform, AMBOSS aims to deliver world-class medical knowledge across the healthcare sector, ensuring every clinician—regardless of their role—can make fast, accurate decisions.
European Stock Corporation Status Paves Way for IPO Ambitions
Alongside the funding, AMBOSS has officially transitioned into a European Stock Corporation (SE)—a strategic move reflecting its long-term vision of becoming a global leader in digital healthcare solutions. This change not only enhances regulatory flexibility across borders but also positions the company for potential future growth, including a public listing.
This corporate evolution strengthens AMBOSS’s market leadership and sets the stage for sustainable expansion as the company scales its operations worldwide.
Empowering the Healthcare Workforce with AI-Driven Medical Insights
Founded in 2012 by physicians Ehsan Khaljani, Madjid Salimi, Benedikt Hochkirchen, and Sievert Weiss, AMBOSS has evolved into a trusted digital co-pilot for healthcare professionals. The platform provides real-time, evidence-based guidance designed to support clinical decision-making while enhancing medical education.
Today, AMBOSS employs over 500 people from 50+ countries, including a dedicated team of more than 150 physicians. This robust in-house medical and tech collaboration drives the platform’s success, enabling it to bridge the gap between vast medical knowledge and everyday clinical practice.
At its core, AMBOSS integrates peer-reviewed medical content with AI-powered insights, delivering practical guidance for diagnosis and treatment. Whether it’s reviewing diagnostic pathways, consulting flowcharts, or accessing acute management checklists, physicians benefit from clear, actionable recommendations designed to reduce errors and improve patient outcomes.
A Trusted Resource for Over 1 Million Healthcare Professionals Globally
In the U.S., AMBOSS has become an essential resource for medical students preparing for exams, with many outperforming traditional study methods thanks to the platform’s interactive tools. Additionally, 25% of first-year U.S. residents rely on AMBOSS to guide their clinical decision-making during the critical transition into residency.
In Germany, the platform is equally vital, influencing nearly half of all inpatient treatments, with physicians turning to AMBOSS for expert guidance on complex cases.
With a global community of more than 1 million healthcare professionals spanning 180 countries, AMBOSS has firmly established itself as a go-to resource for clinicians and students alike.
Ethical AI Integration Enhances Accuracy and Trust in Clinical Practice
AI is deeply embedded in AMBOSS’s operations, enabling the platform to distill complex medical data into concise, evidence-based recommendations. The company maintains a rigorous validation process, ensuring its AI remains ethical, reliable, and clinician-friendly.
By focusing on responsible AI development, AMBOSS helps healthcare professionals stay aligned with evolving clinical guidelines while delivering personalized patient care. Its AI-driven approach not only enhances efficiency but also builds user trust, reinforcing AMBOSS’s role as a reliable partner in modern healthcare.
Strategic Acquisitions and Future IPO Plans Signal Ambitious Growth
AMBOSS’s growth strategy goes beyond organic expansion. In 2024, the company acquired Novaheal, a nursing-focused startup, and NEJM Knowledge+, a U.S. board exam prep platform for medical residents—both strategic moves to strengthen its offerings.
With fresh funding secured, AMBOSS plans to deepen its investments in advanced technology, new healthcare segments, and selective acquisitions, while keeping a potential IPO firmly on the horizon.
“We deliberately chose investors aligned with our long-term vision, many of whom manage evergreen funds and plan to support us through a potential IPO and beyond,” shared Benedikt Hochkirchen, Co-Founder and Co-CEO of AMBOSS. “This capital gives us the flexibility to scale our technology and expand into new markets.”
Co-CEO Dr. Madjid Salimi emphasized the importance of embracing technology: “Healthcare professionals won’t be replaced by technology—but those who harness it will lead the future.”
Echoing this sentiment, Peter Bason, Head of Private Capital at KIRKBI, said, “AMBOSS has shown impressive growth, especially in the U.S., and its platform is quickly becoming indispensable for medical students and healthcare professionals alike. We’re proud to support their mission of empowering the next generation of healthcare professionals worldwide.”
